Yervoy (ipilimumab)

P2, N=51, Active, not recruiting, University of Texas Southwestern Medical Center | N=80 --> 51 | Recruiting --> Active, not recruiting

Rectal cancer recurrence remains a major therapeutic challenge, particularly in patients unresponsive to conventional regimens. While previous studies have demonstrated limited benefit of immunotherapy in this tumor subtype, the present findings suggest an emerging therapeutic opportunity that warrants prospective evaluation to confirm efficacy, explore the mechanistic basis, and identify biomarkers predictive of durable response beyond the absence of liver metastases. More effective combinatorial regimens like zanzalintinib and atezolizumb (STELLAR-303) trial, as well as newer generation of CTLA-4 inhibitors like botensilimab, vilastobart, and muzastotug are showing more promise for patients with MSS colorectal cancers in particular who do not have liver metastases (NLM).

P1/2, N=148, Recruiting, Fondazione NIBIT Onlus | Not yet recruiting --> Recruiting

Therapeutic advances are reshaping the management of nccRCC, with IO/TKI regimens and histology-specific therapies showing promise. Continued integration of molecular classification, rare subtype-specific trials, and international collaboration will be essential to establish evidence-based treatment standards for this diverse and understudied population.

He was started on ipilimumab and nivolumab combination therapy outpatient; however, treatment was held after 2 cycles due to marked transaminitis, and prednisone was initiated for presumed ICI-related hepatitis...Although second-line immunosuppressants were considered, rapid deterioration prompted initiation of tocilizumab. His hospitalization was complicated by multiorgan failure and radiographic progression of CNS metastases, and he ultimately transitioned to comfort care and died on hospital day 7. This case demonstrates hemorrhagic CNS disease at diagnosis alongside early, fulminant, steroid-refractory ICI hepatitis and highlights the need for heightened hepatic surveillance and early escalation of immunosuppression during dual checkpoint blockade.

A 62-year-old female, diagnosed with intermediate IMDC risk metastatic clear cell renal cell cancer, with multifocal metastases to left pleural membrane and primary renal mass in-situ, received combination of 1st line Nivolumab/Ipilimumab therapy. It is thus postulated that the patients omental band developed as a consequence of immune mediated enteritis secondary to immunotherapy. Although small bowel obstruction secondary to immunotherapy is rare, with under five cases in the literature, it is a potentially life-threatening complication that treating physicians need to be aware of.

P3, N=339, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

P2, N=90, Not yet recruiting, Sun Yat-sen University

P1/2, N=50, Recruiting, Amsterdam UMC | Not yet recruiting --> Recruiting

P1/2, N=24, Recruiting, Stichting Amsterdam UMC | Not yet recruiting --> Recruiting

P2, N=57, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Mar 2027 --> Jul 2032 | Trial primary completion date: Mar 2026 --> Jul 2027

P1/2, N=33, Recruiting, West China Hospital